Anzemet (Dolasetron Mesylate Monohydrate) - Summary

ANZEMET SUMMARY

ANZEMET® Tablets
(dolasetron mesylate)

ANZEMET (dolasetron mesylate) is an antinauseant and antiemetic agent.

ANZEMET Tablets are indicated for:

1. the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses;
2. the prevention of postoperative nausea and vomiting.

See all indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Anzemet (Dolasetron)

Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2008.04.29]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 4/29/2008

more news >>

Published Studies Related to Anzemet (Dolasetron)

Inspired oxygen fraction of 0.8 compared with 0.4 does not further reduce postoperative nausea and vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy. [2006.11]
BACKGROUND: Postoperative nausea and vomiting (PONV) is one of the most frequent complications after general anaesthesia. Single-dose antiemetic prophylaxis has limited efficacy in high-risk patients. Adding a simple potential antiemetic approach, such as increasing the inspired oxygen fraction, to the antiemetic portfolio would preserve pharmacological interventions for treatment of symptoms in the postoperative period. However, the antiemetic effect of a high inspired oxygen fraction is still discussed controversially. The aim of the study was to evaluate whether an inspired oxygen fraction of 0.8 decreases PONV in patients receiving the 5-HT(3)-antagonist dolasetron... CONCLUSIONS: An inspired oxygen fraction of 0.8 does not further decrease PONV or vomiting in dolasetron-treated patients undergoing laparoscopic cholecystectomy. The lower incidence of PONV in Groups A and B compared with Group C is most likely caused by the omission of nitrous oxide.

Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. [2006.04]
We investigated the efficacy of granisetron and dolasetron in preventing postoperative nausea and vomiting. Because the metabolism of the various antiemetic 5-hydroxytryptamine type 3 (5-HT3) antagonists involves different isoforms of the hepatic cytochrome P450 system, we examined the relationship between the clinical efficacy of these drugs and polymorphic cytochrome P450 2D6 (CYP2D6) genotype...

Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. [2005.11]
Pruritus is the most common side effect of intrathecal morphine for postoperative pain relief...

Dolasetron versus ondansetron for the treatment of postoperative nausea and vomiting. [2005.02]
The management of postoperative nausea and vomiting (PONV) remains a persistent problem... Because of the decreased use of rescue antiemetics and acquisition cost at our hospital, costs in the dolasetron group were less than costs in the ondansetron group.

Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting. [2004.08]
STUDY OBJECTIVE: To determine if the timing of administration affects the dose of dolasetron necessary to prevent postoperative nausea and vomiting (PONV)... CONCLUSIONS: When dosed near the end of anesthesia, a 12.5 mg IV dose of dolasetron was comparable to higher doses administered at or before induction of anesthesia. Copyright 2004 Elsevier Inc.

more studies >>

Clinical Trials Related to Anzemet (Dolasetron)

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects [Completed]

Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy.

PURPOSE: Randomized phase II/III trial to determine the effectiveness of antiemetic drugs with or without ginger in treating nausea in patients who are receiving chemotherapy for cancer.

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy [Active, not recruiting]
RATIONALE: Pressure or nerve stimulation applied to an acupuncture point on the inside of the wrist may help control nausea and vomiting during chemotherapy.

PURPOSE: Randomized phase II trial to study the effectiveness of acupressure and acustimulation wrist bands in treating nausea and vomiting in patients undergoing chemotherapy for cancer.

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer [Completed]
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy.

PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas [Active, not recruiting]
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11) (also administered at each cycle is zofran/Kytril/Anzemet, decadron, and IV atropine). A treatment cycle is 21 days. Patients will be treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progresses. For patients responding to treatment, therapy may be continued beyond 18 cycles.

At each cycle, patient exams and interviews as well as lab results will help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities will be compared with current side effects.

more trials >>